Loading, Please Wait...
RICHLAND, Wash., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Studies recently reported at scientific meetings and published in medical journals illustrate that Isoray, Inc.’s (NYSE AMERICAN: ISR) Cesium Blu™ is making an important difference in providing treatment options for cancer patients and their doctors. Isoray expects the growing volume of results-based data on Cesium Blu, formerly known as Cesium-131, will help grow market awareness of the range of clinical applications.
Among the recent studies are the findings of Dr. David Brachman of the Barrow Neuroscience Institute on the impact of Cesium Blu-driven treatment on three types of recurrent brain cancers. According to the publication, Surgically Targeted Radiation Therapy: Safety Profile of Collagen Tile Brachytherapy in 79 Recurrent, Previously Irradiated Intracranial Neoplasms on a Prospective Clinical Trial, Cesium-powered GammaTile therapy offers recurrent brain cancer patients a safe and effective treatment. The findings involve patients suffering from high grade gliomas, meningiomas and brain metastases. The results are important because recurrence of these hard to treat brain cancers have left patients with very limited options due to their prior radiation treatments. FDA cleared in July 2018, GammaTile therapy offers promising treatment for patients with these brain cancers.
Another recent study,Long Term Results from a Prospective Randomized Trial of 131Cs vs 125I Permanent Prostate Brachytherapy, was published by Dr. Manui Agarwal of the University of Maryland and Dr. Brian Moran of the Chicago Prostate Cancer Center. It reported long-term follow-up data collected on Cesium-131 as compared to Iodine-125, a long-established prostate brachytherapy isotope. This long-term data with nine-year median follow-up shows comparable long-term biochemical control (PSA recurrence) results between Cesium-131 and Iodine-125 in these patients. The data supports Cesium-131 as an effective long-term solution for these patients and supports Cesium-131 as an optimal choice for prostate cancer patients.
The impact of Cesium-131 on recurring skull base (deep neck) cancers is the focus of a case report in the Journal of Neurological Surgery Reports by Dr. Corey Savard of Thomas Jefferson University Hospital. The joint effort of otolaryngology, radiation oncology and neurosurgical physicians is entitled, Cesium-131 Interstitial Brachytherapy for Recurrent Malignancies of the Skull Base. Presented were two cases of the especially challenging cancers that recur in a very difficult area to treat. The authors stated that the characteristics of Cesium-131 that make it effective in treating other cancers might also make it effective in treating difficult recurring skull base malignancies. Although this is a small study and the results are early, as of the published date there were no recurrences or complications noted in either case.
According to Isoray CEO Lori Woods, studies like these are important for physician awareness and their understanding of the opportunities that Cesium-131 offers. “These studies stand among a number of recent reports providing mounting clinical evidence that illustrates that Cesium Blu is a valuable option for clinicians and patients. As we continue to grow our share of the prostate cancer market, we see additional developing opportunities that we believe hold great promise.”
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium Blu by visiting www.isoray.com. Join us onFacebook and follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about Isoray's future expectations, including: the benefits of renaming our product “Cesium Blu™”, the advantages of our Blu Build and powering of GammaTile™ Therapy, whether interest in and use of our Cesium Blu™ products will increase or continue, whether our new brand identity strategy will continue to increase sales, whether use of Cesium-131 in non-prostate applications will continue to increase revenue, the efficacy of the studies, whether further manufacturing and production process improvements will be completed or will result in lower costs, whether our market presence and growth will continue, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, market acceptance and recognition of our rebranded products, our ability to successfully manufacture, market and sell our Blu Build products and the success of the GammaTile™ Therapy, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released that support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards, the success of our sales and marketing efforts, changes in reimbursement rates, the procedures and regulatory requirements mandated by the FDA for 510(k) approval and reimbursement codes, changes in laws and regulations applicable to our products, the scheduling of physicians who either delay or do not schedule patients in periods anticipated, the use of competitors' products in lieu of our products, less favorable reimbursement rates than anticipated for each of our products, and other risks detailed from time to time in Isoray's reports filed with the SEC. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Media and Public Relations: Sharon Schultz (302) 539-3747 Investor Relations: Mark Levin (501) 255-1910